Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer

被引：0
|
作者：
Kelly, R. [1 ]
Wong, S. S. L. [2 ]
Shapiro, J. [3 ]
Weickhardt, A. J. [4 ]
Parente, P. [5 ]
Azad, A. [6 ]
Uccellini, A. [7 ]
Torres, J. [8 ]
Parnis, F. [9 ]
Kwan, E. [10 ]
Brown, S. [11 ]
Steer, C. [12 ]
Warren, M. [13 ]
Gibbs, P. [14 ]
Anton, A. [1 ]
Tran, B. [1 ]
机构：
[1] Walter Eliza Hall Inst Med Res, Clin Data Clin Trials & Biomarkers, Parkville, Vic, Australia
[2] Sunshine Hosp Western Hlth, Med Affairs Dept, St Albans, Vic, Australia
[3] Alfred Hosp, Med Oncol, Melbourne, Vic, Australia
[4] Olivia Newton John Canc Wellness & Res Ctr, Dept Med Oncol, Heidelberg, Vic, Australia
[5] Box Hill Hosp, Eastern Hlth, Dept Med Oncol, Bldg B, Box Hill, Vic, Australia
[6] Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[7] Austin Hosp, Austin Hlth, Med Oncol, Heidelberg, Vic, Australia
[8] Goulburn Valley Hlth, Dept Med Oncol, Shepparton, Vic, Australia
[9] Adelaide Canc Ctr, Dept Med Oncol, Adelaide, SA, Australia
[10] Monash Canc Ctr, Monash Hlth, Med Oncol, Bentleigh East, Vic, Australia
[11] Ballarat Hlth Serv, Med Oncol, Ballarat Base Hosp, Ballarat, Vic, Australia
[12] Border Med Oncol, Dept Med Oncol, East Albury, Vic, Australia
[13] Bendigo Hlth, Med Oncol, Bendigo, Vic, Australia
[14] WEHI Walter & Eliza Hall Inst Med Res, Dept Oncol, Parkville, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
165P
引用
收藏
页码：S1498 / S1499
页数：2
相关论文
共 50 条
  • [31] Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
    Shiota, Masaki
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 360 - 369
  • [32] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Kai Ozaki
    Shingo Hatakeyama
    Shintaro Narita
    Kenichi Hata
    Takafumi Yanagisawa
    Toshikazu Tanaka
    Kyo Togashi
    Tomoko Hamaya
    Teppei Okamoto
    Hayato Yamamoto
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Takahiro Kimura
    Tomonori Habuchi
    Chikara Ohyama
    World Journal of Urology, 2023, 41 : 67 - 75
  • [33] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Ozaki, Kai
    Hatakeyama, Shingo
    Narita, Shintaro
    Hata, Kenichi
    Yanagisawa, Takafumi
    Tanaka, Toshikazu
    Togashi, Kyo
    Hamaya, Tomoko
    Okamoto, Teppei
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kimura, Takahiro
    Habuchi, Tomonori
    Ohyama, Chikara
    WORLD JOURNAL OF UROLOGY, 2023, 41 (01) : 67 - 75
  • [34] Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer
    Kwan, Edmond M.
    Azad, Arun A.
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 617 - 619
  • [35] Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer
    Du, Xinxing
    Fei, Xiaochen
    Wang, Jialin
    Dong, Yanhao
    Fan, Liancheng
    Yang, Bin
    Chen, Wei
    Gong, Yiming
    Xia, Binbin
    Zhu, Hanjing
    Wu, Fan
    Wang, Yanqing
    Dong, Liang
    Zhu, Yinjie
    Pan, Jiahua
    Yao, Xudong
    Dong, Baijun
    TRANSLATIONAL ONCOLOGY, 2023, 34
  • [36] Rezvilutamide for metastatic hormone-sensitive prostate cancer
    Ye, Dingwei
    Gu, Weijie
    Li, Junliang
    LANCET ONCOLOGY, 2022, 23 (11): : E491 - E491
  • [37] Treatment of metastatic hormone-sensitive prostate cancer
    Rane, Jayant K.
    Chowdhury, Amani
    Kinnaird, William
    Marks, Gillian
    Davda, Reena
    TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
  • [38] Management of Metastatic Hormone-Sensitive Prostate Cancer
    Bernard, Brandon
    Sweeney, Christopher J.
    CURRENT UROLOGY REPORTS, 2015, 16 (03)
  • [39] Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches
    Damodaran, Shivashankar
    Lang, Joshua M.
    Jarrard, David F.
    JOURNAL OF UROLOGY, 2019, 201 (05): : 876 - 885
  • [40] Docetaxel for hormone-sensitive metastatic prostate cancer
    Baker, Holly
    LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
12345